Comparison of Ionis Pharmaceuticals Inc. (IONS) and Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

We will be contrasting the differences between Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Fennec Pharmaceuticals Inc. (NASDAQ:FENC) as far as profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals Inc. 752.47M 11.92 365.62M 2.58 25.76
Fennec Pharmaceuticals Inc. N/A 0.00 10.95M -0.52 0.00

Demonstrates Ionis Pharmaceuticals Inc. and Fennec Pharmaceuticals Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals Inc. 48.59% 39.3% 14.4%
Fennec Pharmaceuticals Inc. 0.00% -41.8% -39.4%

Risk & Volatility

Ionis Pharmaceuticals Inc. has a beta of 2.32 and its 132.00% more volatile than S&P 500. Fennec Pharmaceuticals Inc. on the other hand, has -0.44 beta which makes it 144.00% less volatile compared to S&P 500.

Liquidity

9.4 and 9.4 are the respective Current Ratio and a Quick Ratio of Ionis Pharmaceuticals Inc. Its rival Fennec Pharmaceuticals Inc.’s Current and Quick Ratios are 14 and 14 respectively. Fennec Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Ionis Pharmaceuticals Inc.

Analyst Ratings

The Ratings and Recommendations for Ionis Pharmaceuticals Inc. and Fennec Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ionis Pharmaceuticals Inc. 0 2 1 2.33
Fennec Pharmaceuticals Inc. 0 0 0 0.00

The upside potential is 6.93% for Ionis Pharmaceuticals Inc. with consensus price target of $68.33.

Insider & Institutional Ownership

Institutional investors owned 85.4% of Ionis Pharmaceuticals Inc. shares and 52.1% of Fennec Pharmaceuticals Inc. shares. Insiders owned 0.2% of Ionis Pharmaceuticals Inc. shares. On the other hand, insiders owned about 17.41% of Fennec Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ionis Pharmaceuticals Inc. -3.06% -20.66% 9.91% 29.22% 43.49% 23.1%
Fennec Pharmaceuticals Inc. 0.94% -6.11% -42.13% -43.5% -62.87% -32.6%

For the past year Ionis Pharmaceuticals Inc. had bullish trend while Fennec Pharmaceuticals Inc. had bearish trend.

Summary

Ionis Pharmaceuticals Inc. beats Fennec Pharmaceuticals Inc. on 10 of the 11 factors.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.